Case Studies

Yunfeng Zhu, PharmD Candidate, Diana M. Sobieraj, PharmD, and Craig I. Coleman, PharmD
Published Online: Wednesday, June 19, 2013
Follow Pharmacy_Times:
Case 1
CS, a 77-year-old man recently diagnosed with atrial fibrillation, presents to your pharmacy with a new prescription for dabigatran etexilate 150 mg twice daily. His past medical history is significant for hypertension and type 2 diabetes (and therefore has a CHADS2 score of 3). He is currently taking metoprolol, lisinopril, and metformin. Upon talking with CS you find out that he uses a pillbox to manage his medications.
As CS’s pharmacist, what important counseling point regarding his dabigatran should you offer?
 
Case 2
PH, a 33-year-old woman, presents to your healthcare clinic with a 10-year history of worsening plaque psoriasis currently affecting 15% of her body. The psoriatic plaques are found on both her trunk and extremities. She has tried a variety of topical steroids and a topical vitamin D analog as well as PUVA and NB-UVB phototherapy treatment in the last 3 years, none of which optimally controlled her psoriasis. She has a history of obesity and was recently diagnosed with hypertension for which olmesartan 20 mg daily was prescribed. Her physician asks for your input on which therapy PH should try next for her psoriasis.
How do you, the pharmacist, respond to PH’s physician?


Related Articles
The rate of type 1 diabetes mellitus among non-Hispanic white youth increased significantly over an 8-year period.
As a result of confusing sensations of breathlessness with asthma symptoms, overweight and obese children tend to report poorer asthma control and overuse rescue medications.
A new study indicates that high doses of fish oil supplementation fails to prevent the recurrence of atrial fibrillation.
The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of Novartis’ first-in-class secukinumab therapy for moderate-to-severe plaque psoriasis.
Latest Issues
$auto_registration$